(Q37686622)

22 August 2017

1 reference

title

Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria (English)

1 reference

22 August 2017

main subject

Plasmodium falciparum

0 references

0 references

1

1 reference

22 August 2017

3

Steven R Meshnick

1 reference

22 August 2017

Rushika S Wijesinghe

2

1 reference

22 August 2017

publication date

1 January 2010

1 reference

Lancet Infectious Diseases

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

51-59

1 reference

The dynamics of drug resistance in Plasmodium falciparum

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

The treatment of malaria with a single dose of camoquin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Amodiaquine and hydroxychloroquine resistance in Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Drug-resistant malaria: mechanisms of development and inferences for malaria control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Epidemiology of drug-resistant malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Advances in understanding the genetic basis of antimalarial drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Why is it that antimalarial drug treatments do not always work?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antimalarial dosing regimens and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

World Antimalarial Resistance Network (WARN) IV: clinical pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

The roles of the pfcrt 76T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Malaria treatment efficacy among people living with HIV: the role of host and parasite factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

How malaria has affected the human genome and what human genetics can teach us about malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Influence of hemoglobin E trait on the antimalarial effect of artemisinin derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in Western Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Evidence for a reduced effect of chloroquine against Plasmodium falciparum in alpha-thalassaemic children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Decreased sensitivity of artesunate and chloroquine of Plasmodium falciparum infecting hemoglobin H and/or hemoglobin constant spring erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Resistance to artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Effects of alpha-thalassemia on pharmacokinetics of the antimalarial agent artesunate.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Age- and species-specific duration of infection in asymptomatic malaria infections in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Management of malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

A molecular marker for chloroquine-resistant falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Effect of chloroquine on human lymphocyte proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Effect of malaria chemoprophylaxis on the development of antibodies to Plasmodium falciparum in expatriates living in west Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Lymphocyte response to tetanus toxoid among Indonesian men immunized with tetanus-diphtheria during extended chloroquine or primaquine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Humoral immune response to tetanus-diphtheria vaccine given during extended use of chloroquine or primaquine malaria chemoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Malaria chemoprophylaxis with chloroquine in young Nigerian children. I. Its effect on mortality, morbidity and the prevalence of malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Protection against a malaria challenge by sporozoite inoculation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Frequent and persistent, asymptomatic plasmodium falciparum infections in african infants, characterized by multilocus genotyping

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Chloroquine treatment for uncomplicated childhood malaria in an area with drug resistance: early treatment failure aggravates anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Reducing the burden of malaria in pregnancy by preventive strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Do maternally acquired antibodies protect infants from malaria infection?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Premunition in Plasmodium falciparum infection: insights from the epidemiology of multiple infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Mechanisms of nutrient modulation of the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Pathology of malaria in West Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Diet and cerebral malaria: the effect of famine and refeeding

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Malaria and nutritional status among pre-school children: results from cross-sectional surveys in western Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Increased risk for malaria in chronically malnourished children under 5 years of age in rural Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Malaria and nutritional status in children living on the coast of Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

The relationship between anthropometric measurements and measurements of iron status and susceptibility to malaria in Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Relation of anthropometry to malaria morbidity and immunity in Papua New Guinean children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Influence of wasting and stunting at the onset of the rainy season on subsequent malaria morbidity among rural preschool children in Senegal.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Nutritional status, globulin titers, and parasitic infections of two populations of Tanzanian school children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Impact of child malnutrition on the specific anti-Plasmodium falciparum antibody response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Challenges in the prevention, diagnosis, and treatment of malaria in human immunodeficiency virus infected adults in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Incidence of malaria and efficacy of oral quinine in patients recently infected with human immunodeficiency virus in Kinshasa, Zaire

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Epidemiology and burden of malaria in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anemia in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Malaria in pregnancy: pathogenesis and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Comparative efficacy of chloroquine and sulphadoxine--pyrimethamine in pregnant women and children: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Comparison of the therapeutic efficacy of chloroquine and sulphadoxine-pyremethamine in children and pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Gamma-globulin and acquired immunity to human malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Anti-NANP antibody and treatment efficacy in patients with acute uncomplicated falciparum malaria attacks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Naturally acquired antibodies to the glutamate-rich protein are associated with protection against plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Plasmodium falciparum-infected erythrocytes: agglutination by diverse Kenyan plasma is associated with severe disease and young host age.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

An alteration in concatameric structure is associated with efficient segregation of plasmids in transfected Plasmodium falciparum parasites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

The global distribution and population at risk of malaria: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Neglect of Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970322-6

7 January 2021

10.1016/S1473-3099(09)70322-6

Identifiers

DOI

1 reference

22 August 2017

1 reference